Shionogi & Co., Ltd.
OTC: SGIOF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- CEO
- Isao Teshirogi
- Employees
- 4,955
- Headquarters
- Osaka, Japan
- IPO year
- 2018
- Market cap
- $16.0B
- Website
- https://www.shionogi.com
Loading SGIOF…
Loading profile data…Frequently asked questions about SGIOF
What does Shionogi & Co., Ltd. (SGIOF) do?
Shionogi & Co., Ltd. is a Japanese enterprise focused on the entire lifecycle of pharmaceutical products, diagnostic tools, and medical equipment, encompassing their investigation, creation, production, and supply within Japan. The company's marketed portfolio includes Fetroja, a therapy for multidrug-resistant gram-negative bacterial infections...
Where does SGIOF trade?
Shionogi & Co., Ltd. (SGIOF) trades on the Other OTC.
What sector is SGIOF in?
Shionogi & Co., Ltd. (SGIOF) operates in the Healthcare sector, specifically in the Drug Manufacturers - Specialty & Generic industry.
Who is the CEO of Shionogi & Co., Ltd.?
Isao Teshirogi is the chief executive officer of Shionogi & Co., Ltd. (SGIOF).
Where is Shionogi & Co., Ltd. headquartered?
Shionogi & Co., Ltd. is headquartered in Japan.
Does SGIOF pay a dividend?
Yes — Shionogi & Co., Ltd. (SGIOF) paid a trailing twelve-month dividend of USD 0.46 per share. Frequency and ex-dividend dates are tracked on the dividends tab.
When did SGIOF go public?
Shionogi & Co., Ltd. (SGIOF) completed its initial public offering in 2018.